Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: Effects of synthetic selective NF-kB inhibitor IMD-0354

Cardiovascular Research

Volumn 99, Issue 1, 2013, Pages 35-43

  Hosokawa, Susumu ^a   Haraguchi, Go ^a   Sasaki, Akihito ^a   Arai, Hirokuni ^a   Muto, Susumu ^b   Itai, Akiko ^b   Doi, Shozaburo ^a   Mizutani, Shuki ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Medical Molecular Design Inc   (Japan)

Author keywords

Erk 1 2; Inflammation; MCP 1; NF kB; PAI 1

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBROBLAST GROWTH FACTOR 2; I KAPPA B; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N (3,5 BIS TRIFLUOROMETHY PHENYL) 5 CHLORO 2 HYDROXY BENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; HEART RIGHT VENTRICLE PRESSURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ERK 1/2; INFLAMMATION; MCP-1; NF-KB; PAI-1;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FEEDBACK, PHYSIOLOGICAL; FIBROBLAST GROWTH FACTOR 2; HYPERTENSION, PULMONARY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR RELA; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 84879402375     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt105     Document Type: Article

References (36)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
2. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009;54: 668-675
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537
4. Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdomof the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:2080-2086
5. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling - cellular and molecular mechanisms. Circ Res 2006;99:675-691 (Pubitemid 44498302)
6. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285 (Pubitemid 24165948)
7. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-363 (Pubitemid 36987011)
8. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42, vii (Pubitemid 46335935)
9. Mitani Y, Sawada H, Maruyama J, Jiang BH, Ikeyama Y, Dida FA et al. A nuclear factorkappa B inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007;132:1265-1274 (Pubitemid 47621003)
10. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009;119:512-523
11. Diebold I, Djordjevic T, Hess J, Gorlach A. Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription. Thromb Haemost 2008;100:1021-1028
12. Grassia G, Maddaluno M, Musilli C, De Stefano D, Carnuccio R, Di Lauro MV et al. The I{kappa}B kinase inhibitor nuclear factor-{kappa}B essential modulator-binding domain peptide for inhibition of injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2010;30:2458-2466
13. Raj T, Kanellakis P, Pomilio G, Jennings G, Bobik A, Agrotis A. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein Edeficient mice. Arterioscler Thromb Vasc Biol 2006;26:1845-1851 (Pubitemid 44305339)
14. Watanabe A, Kurabayashi M, Arai M, Sekiguchi K, Nagai R. Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells. Cardiovasc Res 2001;51:151-159 (Pubitemid 32523064)
15. OnaiY, Suzuki J, KakutaT, MaejimaY, Haraguchi G, FukasawaHet al. Inhibitionof IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;63:51-59 (Pubitemid 38759809)
16. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006;114: 912-920 (Pubitemid 44337134)
17. Yang C-M, Luo S-F, Hsieh H-L, Chi P-L, Lin C-C, Wu C-C et al. Interleukin-1b induces ICAM-1 expression enhancing leukocyte adhesion in human rheumatoid arthritis synovial fibroblasts: Involvement of ERK, JNK, AP-1, and NF-kB. J Cell Physiol 2010;224: 516-526
18. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004; 101:5634-5639 (Pubitemid 38481208)
19. Lin CC, Lin WN,Wang WJ, Sun CC, Tung WH,Wang HH et al. Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB. Cardiovasc Res 2009;82:522-531
20. Cowan KN, Jones PL, Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 1999;84:1223-1233 (Pubitemid 29244784)
21. Mandegar M, FungYC, HuangW, RemillardCV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004;68:75-103 (Pubitemid 39093882)
22. Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004;126:1255-1261 (Pubitemid 39391258)
23. TuL,Dewachter L, GoreB, Fadel E, Dartevelle P, SimonneauGet al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:311-322
24. Zimmerman MA, Selzman CH, Reznikov LL, Raeburn CD, Barsness K, McIntyre RC Jr. et al. Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 2002;283:H175-H180 (Pubitemid 34705337)
25. Lille S, Daum G, Clowes MM, Clowes AW. The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery. J Surg Res 1997;70:178-186 (Pubitemid 27315204)
26. Chen Y, Kelm RJ Jr., Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004;92:178-188
27. Kouri FM, QueisserMA, Konigshoff M,Chrobak I, PreissnerKT, SeegerWet al. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Int J Biochem Cell Biol 2008;40:1872-1882
28. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H et al. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2006;173:1016-1022
29. Zheng JP, Zhang Y, Edvinsson L, Hjalt T, Xu CB. NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resistance arteries. Eur J Pharmacol 2010;637:148-154
30. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-552 (Pubitemid 44267025)
31. Schultze AE, Roth RA. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1993;121:129-137 (Pubitemid 23221282)
32. Diebold I, Kraicun D, Bonello S, Gorlach A. The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 2008;100:984-991
33. Morimoto H, Hirose M, Takahashi M, Kawaguchi M, Ise H, Kolattukudy PE et al. MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 2008;78:554-562 (Pubitemid 351769764)
34. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M et al. Role of endotheliumderived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;176:1041-1047 (Pubitemid 350127849)
35. Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc Ther 2010;28:8-14
36. Lo IC, Shih J-M, Jiang MJ. Reactive oxygen species and ERK1/2 mediate monocyte chemotactic protein-1-stimulatedsmooth muscle cell migration. J Biomed Sci 2005;12:377-388. (Pubitemid 40897643) Technology